$PRTA
PROTHENA CORP PUBLIC LTD CO

2024 Q4 Form 10-Q Financial Statement

#000155905324000032 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $970.0K
YoY Change -98.86%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.76M
YoY Change 0.96%
% of Gross Profit
Research & Development $50.72M
YoY Change -12.42%
% of Gross Profit
Depreciation & Amortization $200.0K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $67.48M
YoY Change -9.49%
Operating Profit -$66.51M
YoY Change -745.26%
Interest Expense $6.743M
YoY Change -20.67%
% of Operating Profit
Other Income/Expense, Net $6.677M
YoY Change -21.51%
Pretax Income -$59.84M
YoY Change -418.02%
Income Tax -$800.0K
% Of Pretax Income
Net Earnings -$59.00M
YoY Change -369.32%
Net Earnings / Revenue -6082.58%
Basic Earnings Per Share -$1.10
Diluted Earnings Per Share -$1.10
COMMON SHARES
Basic Shares Outstanding 53.81M shares 53.78M shares
Diluted Shares Outstanding 53.79M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $519.3M
YoY Change -22.6%
Cash & Equivalents $519.3M
Short-Term Investments
Other Short-Term Assets $15.72M
YoY Change 8.43%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $535.0M
YoY Change -22.53%
LONG-TERM ASSETS
Property, Plant & Equipment $3.254M
YoY Change 33.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.754M
YoY Change -64.17%
Total Long-Term Assets $60.27M
YoY Change 7.02%
TOTAL ASSETS
Total Short-Term Assets $535.0M
Total Long-Term Assets $60.27M
Total Assets $595.3M
YoY Change -20.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.33M
YoY Change -46.91%
Accrued Expenses $24.82M
YoY Change -18.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $46.42M
YoY Change -13.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $14.47M
YoY Change
Total Long-Term Liabilities $14.47M
YoY Change -81.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.42M
Total Long-Term Liabilities $14.47M
Total Liabilities $60.89M
YoY Change -53.05%
SHAREHOLDERS EQUITY
Retained Earnings -$1.000B
YoY Change 9.58%
Common Stock $538.0K
YoY Change 0.37%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $534.4M
YoY Change
Total Liabilities & Shareholders Equity $595.3M
YoY Change -20.31%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$59.00M
YoY Change -369.32%
Depreciation, Depletion And Amortization $200.0K
YoY Change 0.0%
Cash From Operating Activities -$45.19M
YoY Change -575.64%
INVESTING ACTIVITIES
Capital Expenditures $9.000K
YoY Change -98.2%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.000K
YoY Change -98.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 333.0K
YoY Change -87.67%
NET CHANGE
Cash From Operating Activities -45.19M
Cash From Investing Activities -9.000K
Cash From Financing Activities 333.0K
Net Change In Cash -44.86M
YoY Change -483.44%
FREE CASH FLOW
Cash From Operating Activities -$45.19M
Capital Expenditures $9.000K
Free Cash Flow -$45.20M
YoY Change -602.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Country
EntityAddressCountry
IE
dei Trading Symbol
TradingSymbol
PRTA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
53808732 shares
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
618830000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5159000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13941000 usd
CY2023Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
1352000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
639282000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12162000 usd
CY2023Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
33893000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
860000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6349000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
57100000 usd
CY2023Q4 us-gaap Assets
Assets
696382000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
25391000 usd
CY2023Q4 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
14724000 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
0 usd
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
67405000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
78126000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
135017000 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2023Q4 prta Deferred Shares Value
DeferredSharesValue
0 usd
CY2023Q4 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2024Q3 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
537000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53682117 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53682117 shares
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1540859000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-980031000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
561365000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
696382000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
84866000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
91054000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
57913000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172347000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-89664000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-112521000 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8522000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
22912000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-253000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
8507000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
20235000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18815000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3092000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5075000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10310000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
21907000 usd
us-gaap Net Income Loss
NetIncomeLoss
-64354000 usd
us-gaap Net Income Loss
NetIncomeLoss
-79552000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53559000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53757000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53064000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58004000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
29834000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-11712000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5221000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-768000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18496000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102278000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
255000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1908000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1613000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-100920000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
621042000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
712618000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2412000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
93000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3810000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
519262000 usd
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
860000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001559053
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1111119
dei Entity Address Address Line1
EntityAddressAddressLine1
77 Sir John Rogerson’s Quay, Block C
dei Entity Address Address Line2
EntityAddressAddressLine2
Grand Canal Docklands
dei Entity Address City Or Town
EntityAddressCityOrTown
Dublin 2,
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
D02 VK60,
dei Country Region
CountryRegion
353
dei City Area Code
CityAreaCode
1
dei Security12b Title
Security12bTitle
Ordinary Shares, par value $0.01 per share
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
519262000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15722000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
534984000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3836000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11400000 usd
CY2024Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
41002000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
860000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3754000 usd
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
60270000 usd
CY2024Q3 us-gaap Assets
Assets
595254000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10330000 usd
CY2024Q3 prta Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
10340000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8832000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2613000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14307000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
46422000 usd
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5589000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8881000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
133034000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22659000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-69429000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-89862000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53757000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53064000 shares
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
520122000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
673109000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-59001000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-66000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-194000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5159000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-29014000 usd
dei Local Phone Number
LocalPhoneNumber
236-2500
CY2024Q3 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
PROTHENA CORPORATION PUBLIC LIMITED COMPANY
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
L2
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14470000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
60892000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2024Q3 prta Deferred Shares Value
DeferredSharesValue
0 usd
CY2024Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2023Q4 prta Deferred Shares Share Issued
DeferredSharesShareIssued
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53808732 shares
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1578209000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1044385000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
534362000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
595254000 usd
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
6743000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
20429000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-835000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-59001000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53790000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53790000 shares
us-gaap Net Income Loss
NetIncomeLoss
-64354000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
672000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35444000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-7109000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5159000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-20289000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1585000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4810000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-82868000 usd
us-gaap Payments To Acquire Machinery And Equipment
PaymentsToAcquireMachineryAndEquipment
1261000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1261000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20972000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44620000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-39509000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
384000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
670897000 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
1352000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
860000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
520122000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
673109000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
561365000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12383000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
890000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-72239000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
502399000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12041000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
591000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
66886000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
581917000 usd
dei Document Type
DocumentType
10-Q
dei Entity File Number
EntityFileNumber
001-35676
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3254000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1114000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15662000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
56891000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10721000 usd
CY2023Q4 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
538000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53808732 shares
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
970000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50723000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
158680000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16760000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16645000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
50351000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44895000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
67483000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
74558000 usd
us-gaap Operating Expenses
OperatingExpenses
222698000 usd
us-gaap Operating Expenses
OperatingExpenses
203575000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-66513000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
10308000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
6677000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59836000 usd
us-gaap Net Income Loss
NetIncomeLoss
-79552000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
652000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6824000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-52984000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-255000 usd
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
71000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
217000 usd
prta Noncash Or Part Noncash Reclassification Of Prepaid Lease Payments To Right Of Use Assets Upon Lease Commencement
NoncashOrPartNoncashReclassificationOfPrepaidLeasePaymentsToRightOfUseAssetsUponLeaseCommencement
0 usd
prta Noncash Or Part Noncash Reclassification Of Prepaid Lease Payments To Right Of Use Assets Upon Lease Commencement
NoncashOrPartNoncashReclassificationOfPrepaidLeasePaymentsToRightOfUseAssetsUponLeaseCommencement
7522000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11020000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
426000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2024Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
534362000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
622042000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8790000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2540000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-46864000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
607409000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10100000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15659000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-54595000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
581679000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10944000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2711000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
21907000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
617227000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1000000000.0 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
519300000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with U.S. GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to revenue recognition and research and development expenses. Th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company places its cash equivalents with high credit quality financial institutions and, by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks have exceeded, and will continue to exceed, federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s business is primarily conducted in U.S. dollars except for its agreements with contract manufacturers for drug supplies which are primarily denominated in Euros. The Company recor</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ded a loss on foreign currency exchange rate differences of approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$194,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$253,000 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the nine months ended September 30, 2024, and 2023, respectively. If the Company increases its business activities that require t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he use of foreign currencies, it may be exposed to losses if the Euro and other such currencies continue to strengthen against the U.S. dollar.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2024, and December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, of the Company’s property and equipment, net was held in the U.S. and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a nominal amount was in Ireland</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other late-stage clinical biotechnology companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its drug candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s drug candidates, its right to develop and commercialize its drug candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, and the need to secure and maintain adequate clinical trial management, manufacturing, packaging, labeling, storage, testing, and distribution arrangements with third parties. The Company also relies on third-party consultants to assist in managing these third parties and assist with its clinical trial operations and manufacturing. If the Company does not successfully commercialize or partner any of its drug candidates, it will be unable</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to generate product revenue or achieve profitability. Further, the Company is also subject to broad market risks and uncertainties resulting from recent events, such as inflation, rising interest rates, and recession risks, as well as supply chain and labor shortages.</span></div>
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
194000 usd
us-gaap Foreign Currency Transaction Loss Before Tax
ForeignCurrencyTransactionLossBeforeTax
253000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2024Q3 prta Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
13120000 usd
CY2023Q4 prta Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
10998000 usd
CY2024Q3 prta Prepaid General And Administrative Expense
PrepaidGeneralAndAdministrativeExpense
1537000 usd
CY2023Q4 prta Prepaid General And Administrative Expense
PrepaidGeneralAndAdministrativeExpense
803000 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1065000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2140000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15722000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13941000 usd
CY2024Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9137000 usd
CY2023Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
9019000 usd
CY2024Q3 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
2204000 usd
CY2023Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
2232000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11341000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11251000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8087000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7415000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
200000 usd
us-gaap Depreciation
Depreciation
700000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
200000 usd
us-gaap Depreciation
Depreciation
700000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11869000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13245000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
999000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
288000 usd
CY2024Q3 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
1439000 usd
CY2023Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
2129000 usd
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14307000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
15662000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-59001000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
21907000 usd
us-gaap Net Income Loss
NetIncomeLoss
-64354000 usd
us-gaap Net Income Loss
NetIncomeLoss
-79552000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53790000 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53559000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53757000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
53064000 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53790000 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
58004000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53757000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
53064000 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.50
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.38
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.50
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11321000 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2137000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11321000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9966000 shares
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
808000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3188000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3158000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3269000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2523000 usd
CY2024Q3 prta Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
0 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
12946000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1452000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
11494000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
8000000.0 usd
CY2024Q3 us-gaap Contractual Obligation
ContractualObligation
300000 usd
CY2024Q3 us-gaap Purchase Obligation
PurchaseObligation
8036000 usd
CY2024Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
7664000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
269000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
103000 usd
CY2024Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 usd
CY2024Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 usd
CY2024Q3 prta Purchase Obligation To Be Paid After Year Four
PurchaseObligationToBePaidAfterYearFour
0 usd
CY2024Q3 prta Purchaseand Contractual Obligation Total
PurchaseandContractualObligationTotal
8359000 usd
CY2024Q3 prta Purchaseand Contractual Obligation Remainderof Fiscal Year
PurchaseandContractualObligationRemainderofFiscalYear
7713000 usd
CY2024Q3 prta Purchase And Contractual Obligation Due In Year One
PurchaseAndContractualObligationDueInYearOne
333000 usd
CY2024Q3 prta Purchaseand Contractual Obligation Duein Second Year
PurchaseandContractualObligationDueinSecondYear
163000 usd
CY2024Q3 prta Purchaseand Contractual Obligation Duein Third Year
PurchaseandContractualObligationDueinThirdYear
60000 usd
CY2024Q3 prta Purchaseand Contractual Obligation Duein Fourth Year
PurchaseandContractualObligationDueinFourthYear
45000 usd
CY2024Q3 prta Purchase And Contractual Obligation Due After Fourth Year
PurchaseAndContractualObligationDueAfterFourthYear
45000 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8800000 usd
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5600000 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
53808732 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
53808732 shares
prta Numberof Votes
NumberofVotes
1 vote
CY2024Q3 prta Deferred Shares Shares Authorized
DeferredSharesSharesAuthorized
10000 shares
CY2024Q3 prta Deferred Shares Par Value
DeferredSharesParValue
22
CY2024Q3 prta Deferred Shares Share Outstanding
DeferredSharesShareOutstanding
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4029431 shares
CY2024Q3 prta Share Based Payment Arrangement Estimated Forfeiture Rate
ShareBasedPaymentArrangementEstimatedForfeitureRate
0.07
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
84900000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M28D
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
11020000 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
10944000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
35444000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
29834000 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
2000000.0 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
1900000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
6300000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
5300000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
40.83
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
37.67
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9866337 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
29.06
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M6D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
118447000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2156450 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
29.45
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
125615 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
15.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
470719 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
36.14
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
129710 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
30.92
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11296743 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11170000 usd
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
10968503 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
28.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y1M28D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
11169000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
7521340 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
24.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2024Q3 prta Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Related To Vested Options
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueRelatedToVestedOptions
11125000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5100000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3100000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10300000 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001559053-24-000032-index-headers.html Edgar Link pending
0001559053-24-000032-index.html Edgar Link pending
0001559053-24-000032.txt Edgar Link pending
0001559053-24-000032-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
headerlogo.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
prta-20240930.htm Edgar Link pending
prta-20240930.xsd Edgar Link pending
prta2024q310-qxex311.htm Edgar Link pending
prta2024q310-qxex312.htm Edgar Link pending
prta2024q310-qxex321.htm Edgar Link pending
prta2024q3ex-102promotionl.htm Edgar Link pending
prta2024q3exx101selkoecons.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
prta-20240930_cal.xml Edgar Link unprocessable
prta-20240930_def.xml Edgar Link unprocessable
prta-20240930_lab.xml Edgar Link unprocessable
prta-20240930_pre.xml Edgar Link unprocessable
prta-20240930_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable